Other single compounds

(Unterschied zwischen Versionen)

Wechseln zu: Navigation, Suche

Version vom 18. Juni 2020, 13:56 Uhr

Ivermectin
32330482 ä. Ivermectin and COVID-19: a report in Antiviral Research, widespread interest, an FDA warning, two letters to the editor and the authors responses
32251768 2020. The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro
32283237 ä. Hydroxychloroquine and ivermectin: a synergistic combination for COVID-19 chemoprophylaxis and/or treatment?

on ivermectin

32322397 2020. Potential use of hydroxychloroquine, ivermectin and azithromycin drugs in fighting COVID-19: trends, scope and relevance
32314704 2020. Ivermectin and Novel Coronavirus Disease (COVID-19): Keeping Rigor in Times of Urgency
32378737 2020. The Approved Dose of Ivermectin Alone is not the Ideal Dose for the Treatment of COVID-19

Icatibant bradykinin antagonist
32359101 2020. A hypothesized role for dysregulated bradykinin signaling in COVID-19 respiratory complications

Macrolide antibiotics
32249257 2020. Macrolide treatment for COVID-19: Will this be the way forward?

Azithromycin
32302411 2020. Clinical Pharmacology Perspectives on the Antiviral Activity of Azithromycin and Use in COVID-19

Teicoplanin
32179150 ä. Teicoplanin: an alternative drug for the treatment of coronavirus COVID-19?

Doxycycline and other Tetracyclins
32339778 ä. Dapsone and Doxycycline could be potential treatment modalities for COVID-19
32314492 ä. Doxycycline, a widely used antibiotic in dermatology with a possible anti?inflammatory action against IL?6 in COVID?19 outbreak
32267566 2020. Therapeutic Potential for Tetracyclines in the Treatment of COVID-19

Metronidazole retarget
32259129 2020. Metronidazole; a Potential Novel Addition to the COVID-19 Treatment Regimen

Oleoylethanolamide
32327293 ä. Oleoylethanolamide, A Bioactive Lipid Amide, as A Promising Treatment Strategy for Coronavirus/COVID-19

Lauric acid nat. compd.

call for trial

Nicotine nat. toxin

france

32353120 ä. Does Cigarette Smoking Protect Against SARS-CoV-2 Infection?
32242236 ä. COVID-19 and Smoking

Dipyridamole retarget
32318327 ä. Potential therapeutic effects of dipyridamole in the severely ill patients with COVID-19

Various Leads

32251767 2020. Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro
32226695 ä. Acetazolamide, Nifedipine and Phosphodiesterase Inhibitors: Rationale for Their Utilization as Adjunctive Countermeasures in the Treatment of Coronavirus Disease 2019 (COVID-19)

PDE5 Inhibitors
32272196 2020. Any possible role of phosphodiesterase type 5 inhibitors in the treatment of severe COVID19 infections? A lesson from urology
32226695 ä. Acetazolamide, Nifedipine and Phosphodiesterase Inhibitors: Rationale for Their Utilization as Adjunctive Countermeasures in the Treatment of Coronavirus Disease 2019 (COVID-19)

Glycyrrhizin
32335281 ä. Pharmacological perspective: glycyrrhizin may be an efficacious therapeutic agent for COVID-19

Ipecac
32245264 2020. Emetine, Ipecac, Ipecac Alkaloids and Analogues as Potential Antiviral Agents for Coronaviruses

Camostat mesilate
32347443 ä. Camostat mesilate therapy for COVID-19

Nafamostat mesilate
32312781 2020. Nafamostat Mesylate Blocks Activation of SARS-CoV-2: New Treatment Option for COVID-19
32302456 2020. Potential of heparin and nafamostat combination therapy for COVID-19

Sodium pyruvate
32378817 2020. Inhaled Nebulized Sodium Pyruvate Use in COVID-19 Patients

alpha1 adrenergic antagonists
32352407 2020. Preventing cytokine storm syndrome in COVID-19 using alpha-1 adrenergic receptor antagonists
32237190 ä. What does androgenetic alopecia have to do with COVID?19? An insight into a potential new therapy

Ciclesonide
32362440 ä. Therapeutic potential of ciclesonide inhalation for COVID-19 pneumonia: Report of three cases

Melatonin
32217117 2020. COVID-19: Melatonin as a potential adjuvant treatment
32360622 2020. Comment on Melatonin as a potential adjuvant treatment for COVID-19
32334009 2020. Correspondence COVID-19: Melatonin as a potential adjuvant treatment
32347747 2020. Can melatonin reduce the severity of COVID-19 pandemic?
32314850 2020. Melatonin: Roles in influenza, Covid?19, and other viral infections

cannabinoids
32360437 ä. SARS-CoV2 induced respiratory distress: Can cannabinoids be added to anti-viral therapies to reduce lung inflammation?
32273254 2020. Cannabidiol as prophylaxis for SARS-CoV-2 and COVID-19? Unfounded claims versus potential risks of medications during the pandemic

Oxytocin
32344303 ä. Oxytocin as a potential defence against Covid-19?

Resiniferatoxin
32292906 2020. The role of afferent pulmonary innervation in ARDS associated with COVID-19 and potential use of resiniferatoxin to improve prognosis: A review

TRPV1 target
C7147214 ä. Potential TRPV1 blockade to treat severe lung dysfunction in COVID-19 infection
32292907 2020. Standing out from the crowd in treating COVID-19 the title has been idioted from Potential TRPV1 blockade to treat severe lung dysfunction in COVID-19 infection.

Botox
32352081 ä. Perspectives for the use of therapeutic Botulinum toxin as a multifaceted candidate drug to attenuate COVID-19

PAK-1 target
32313880 ä. PAK1-blockers: Potential Therapeutics against COVID-19?
32348877 ä. Chemical evolution for taming the ?pathogenic kinase? PAK1

Endothelin antagonists
32361169 2020. Why not consider an endothelin receptor antagonist against SARS?CoV?2?

Saikosaponins
32353743 2020. Purposing Saikosaponins for the treatment of COVID-19
32345124 2020. An in-silico evaluation of different Saikosaponins for their potency against SARS-CoV-2 using NSP15 and fusion spike glycoprotein as targets

Dapsone
32344275 2020. Dapsone, colchicine and olanzapine as treatment adjuncts to prevent COVID-19 associated adult respiratory distress syndrome (ARDS)
32339778 ä. Dapsone and Doxycycline could be potential treatment modalities for COVID-19
31931639 2020. Dapsone as treatment adjunct in ARDS

Colchicine
32344275 2020. Dapsone, colchicine and olanzapine as treatment adjuncts to prevent COVID-19 associated adult respiratory distress syndrome (ARDS)

32380315 2020. Continuous hydroxychloroquine or colchicine therapy does not prevent infection with SARS-CoV-2: Insights from a large healthcare database analysis

Olanzapine
32344275 2020. Dapsone, colchicine and olanzapine as treatment adjuncts to prevent COVID-19 associated adult respiratory distress syndrome (ARDS)

ADAM17 as target
32291449 ä. ADAM17 inhibition may exert a protective effect on COVID-19

Dextrometorphan

dextrometorphan (antitussive compd)

Rho kinase inhibitors
32283223 2020. Plausibility of therapeutic effects of Rho kinase inhibitors against Severe Acute Respiratory Syndrome Coronavirus 2 (COVID-19)

Nitazoxaide
32360581 ä. Nitazoxanide/Azithromycin combination for COVID-19: A suggested new protocol for COVID-19 early management

tPA

32312290 2020. Salvage use of tissue plasminogen activator (tPA) in the setting of acute respiratory distress syndrome (ARDS) due to COVID-19 in the USA: a Markov decision analysis

31856018 2020. Is there a role for tissue plasminogen activator as a novel treatment for refractory COVID-19 associated acute respiratory distress syndrome?

Plasminogen
32275753 ä. Plasminogen improves lung lesions and hypoxemia in patients with COVID-19

Metformin
32313883 2020. Inhaled biguanides and mTOR inhibition for influenza and coronavirus (Review)
32347974 2020. Metformin and COVID-19: A novel deal of an Old Drug

mTOR ihibitors
32313883 2020. Inhaled biguanides and mTOR inhibition for influenza and coronavirus (Review)
32334502 2020. The Mechanistic Target of Rapamycin (mTOR): Novel Considerations as an Antiviral Treatment

Cyclophilin A inhibitors
32347055 2020. Role of cyclophilin A during coronavirus replication and the antiviral activities of its inhibitors

Alisporivir

32376613 2020. Inhibition of SARS-CoV-2 infection by the cyclophilin inhibitor Alisporivir (Debio 025)

Cyclosporin A
32354685 ä. Why choose cyclosporin A as first-line therapy in COVID-19 pneumonia

CD147
32307653 ä. CD147 as a Target for COVID-19 Treatment: Suggested Effects of Azithromycin and Stem Cell Engagement

Bee venom
32360140 ä. Bee venom and SARS-CoV-2

Spironolactone
32297520 2020. Can spironolactone be used to prevent COVID-19-induced acute respiratory distress syndrome in patients with hypertension?

Imatinib
32376403 ä. Imatinib might constitute a treatment option for lung involvement in COVID-19

Luteolin
32339387 2020. COVID-19, pulmonary mast cells, cytokine storms, and beneficial actions of luteolin

BTK Bruton Tyrosine Kinase ibrutiib
32302379 2020. The BTK inhibitor ibrutinib may protect against pulmonary injury in COVID-19-infected patients

alpha 1 antagonists cave fehlt 1 x

bradykinin antagonists cave felt was

32337769 2020. (tt bradykinin) Noscapine, a possible drug candidate for attenuation of cytokine release associated with SARS-CoV-2

32359101 2020. A hypothesized role for dysregulated bradykinin signaling in COVID-19 respiratory complications

Erythropoietin
32270515 2020. Does recombinant human Erythropoietin administration in critically ill COVID-19 patients have miraculous therapeutic effects?

Celastrol
32347602 2020. Should we try the antiinflammatory natural product, celastrol, for COVID-19?

1
32352871 2020. A Radiation Mitigator as a Potential Treatment for COVID-19

Ozone
C7203037 ä. (Vitamin-C; Ozone)Two known therapies could be useful as adjuvant therapy in critical patients infected by COVID-19?

Thalidomide
C7186126 ä. Proposed use of thalidomide for the cytokine storm of COVID-19

stimulating the Platelets

32315397 2020. Promoting platelets is a therapeutic option to combat severe viral infection of the lung

Thrombomodulin
23607598 2013. (x)Involvement of high mobility group box 1 and the therapeutic effect of recombinant thrombomodulin in a mouse model of severe acute respiratory distress syndrome

Chlorpromazine
32387014 ä. Repositionnement de la chlorpromazine ... psychiatric patients could be protected from severe forms of COVID-19 by their psychotropic treatments

paper

nAChR as target
32387130 ä. GTS-21, an alpha7nAChR agonist, suppressed the production of key inflammatory mediators by PBMCs that are elevated in COPD patients and associated with impaired lung function

Lithium
32408073 2020. Lithium for the 2019 novel coronavirus

Resolvins
32416413 2020. Covid-19 management with inflammation resolving mediators? Perspectives and potential

beta adrenergic antagonists
32388480 2020. Can beta-adrenergic blockers be used in the treatment of COVID-19?

Copper
32388476 2020. Is copper beneficial for COVID-19 patients?

5-Fluorouracil 5-FU
32438240 2020. 5-Fluorouracil in combination with deoxyribonucleosides and deoxyribose as possible therapeutic options for the Coronavirus, COVID-19 infection

Nitric oxide
32387333 ä. Could nasal nitric oxide help to mitigate the severity of COVID-19?

@@ Zeile 22: / Zeile 22: @@
 {{tp|p=32179150|t=ä. Teicoplanin: an alternative drug for the treatment of coronavirus COVID-19?|pdf=|usr=}}
-'''Doxycycline'''
+'''Doxycycline and other Tetracyclins'''
 {{tp|p=32339778|t=ä. Dapsone and Doxycycline could be potential treatment modalities for COVID-19 |pdf=|usr=}}
 {{tp|p=32314492|t=ä. Doxycycline, a widely used antibiotic in dermatology with a possible anti?inflammatory action against IL?6 in COVID?19 outbreak |pdf=|usr=}}
+{{tp|p=32267566|t=2020. Therapeutic Potential for Tetracyclines in the Treatment of COVID-19 |pdf=|usr=}}
 '''Metronidazole''' retarget
@@ Zeile 32: / Zeile 32: @@
 '''Oleoylethanolamide'''
 {{tp|p=32327293|t=ä. Oleoylethanolamide, A Bioactive Lipid Amide, as A Promising Treatment Strategy for Coronavirus/COVID-19 |pdf=|usr=}}
-'''Chlorpromazine''' retarget
-*[https://www.biorxiv.org/content/10.1101/2020.05.05.079608v1 paper]
@@ Zeile 63: / Zeile 59: @@
-'''cannabinoids'''
-{{tp|p=32360437|t=ä. SARS-CoV2 induced respiratory distress: Can cannabinoids be added to anti-viral therapies to reduce lung inflammation?|pdf=|usr=}}
 '''PDE5 Inhibitors'''
 {{tp|p=32272196|t=2020. Any possible role of phosphodiesterase type 5 inhibitors in the treatment of severe COVID19 infections? A lesson from urology |pdf=|usr=}}
 {{tp|p=32226695|t=ä. Acetazolamide, Nifedipine and Phosphodiesterase Inhibitors: Rationale for Their Utilization as Adjunctive Countermeasures in the Treatment of Coronavirus Disease 2019 (COVID-19) |pdf=|usr=}}
-'''Amantadine'''
-{{tp|p=32361028|t=ä. Amantadine disrupts lysosomal gene expression; a hypothesis for COVID19 treatment ? |pdf=|usr=}}
-{{tp|p=32361100|t=2020. Amantadine as a drug to mitigate the effects of COVID-19 |pdf=|usr=}}
@@ Zeile 87: / Zeile 77: @@
 '''Nafamostat mesilate'''
 {{tp|p=32312781|t=2020. Nafamostat Mesylate Blocks Activation of SARS-CoV-2: New Treatment Option for COVID-19 |pdf=|usr=}}
+{{tp|p=32302456|t=2020. Potential of heparin and nafamostat combination therapy for COVID-19 |pdf=|usr=}}
 '''Sodium pyruvate'''
@@ Zeile 104: / Zeile 97: @@
 {{tp|p=32334009|t=2020. Correspondence COVID-19: Melatonin as a potential adjuvant treatment |pdf=|usr=}}
 {{tp|p=32347747|t=2020. Can melatonin reduce the severity of COVID-19 pandemic?|pdf=|usr=}}
+{{tp|p=32314850|t=2020. Melatonin: Roles in influenza, Covid?19, and other viral infections |pdf=|usr=}}
+'''cannabinoids'''
+{{tp|p=32360437|t=ä. SARS-CoV2 induced respiratory distress: Can cannabinoids be added to anti-viral therapies to reduce lung inflammation?|pdf=|usr=}}
+{{tp|p=32273254|t=2020. Cannabidiol as prophylaxis for SARS-CoV-2 and COVID-19? Unfounded claims versus potential risks of medications during the pandemic |pdf=|usr=}}
@@ Zeile 115: / Zeile 113: @@
 '''TRPV1 target'''
 {{tp|p=C7147214|t=ä. Potential TRPV1 blockade to treat severe lung dysfunction in COVID-19 infection |pdf=|usr=}}
+{{tp|p=32292907|t=2020. Standing out from the crowd in treating COVID-19 |pdf=|usr=}} the title has been idioted from ''Potential TRPV1 blockade to treat severe lung dysfunction in COVID-19 infection.''
 '''Botox'''
@@ Zeile 121: / Zeile 120: @@
 '''PAK-1 target'''
 {{tp|p=32313880|t=ä. PAK1-blockers: Potential Therapeutics against COVID-19? |pdf=|usr=}}
+{{tp|p=32348877|t=ä. Chemical evolution for taming the ?pathogenic kinase? PAK1 |pdf=|usr=}}
 '''Endothelin antagonists'''
@@ Zeile 134: / Zeile 136: @@
 {{tp|p=32344275|t=2020. Dapsone, colchicine and olanzapine as treatment adjuncts to prevent COVID-19 associated adult respiratory distress syndrome (ARDS) |pdf=|usr=}}
 {{tp|p=32339778|t=ä. Dapsone and Doxycycline could be potential treatment modalities for COVID-19 |pdf=|usr=}}
+{{tp|p=31931639|t=2020. Dapsone as treatment adjunct in ARDS |pdf=|usr=}}
 '''Colchicine'''
 {{tp|p=32344275|t=2020. Dapsone, colchicine and olanzapine as treatment adjuncts to prevent COVID-19 associated adult respiratory distress syndrome (ARDS) |pdf=|usr=}}
-{{tp|p=32380315|t=ä. Continuous hydroxychloroquine or colchicine therapy does not prevent infection with SARS-CoV-2: Insights from a large healthcare database analysis |pdf=|usr=}}
+{{tp|p=32380315|t=2020. Continuous hydroxychloroquine or colchicine therapy does not prevent infection with SARS-CoV-2: Insights from a large healthcare database analysis |pdf=|usr=}}
@@ Zeile 162: / Zeile 164: @@
 '''tPA'''
 {{ttp|p=32312290|t=2020. Salvage use of tissue plasminogen activator (tPA) in the setting of acute respiratory distress syndrome (ARDS) due to COVID-19 in the USA: a Markov decision analysis |pdf=|usr=}}
+{{ttp|p=31856018|t=2020. Is there a role for tissue plasminogen activator as a novel treatment for refractory COVID-19 associated acute respiratory distress syndrome?|pdf=|usr=}}
 '''Plasminogen'''
@@ Zeile 168: / Zeile 173: @@
 '''Metformin'''
 {{tp|p=32313883|t=2020. Inhaled biguanides and mTOR inhibition for influenza and coronavirus (Review) |pdf=|usr=}}
+{{tp|p=32347974|t=2020. Metformin and COVID-19: A novel deal of an Old Drug |pdf=|usr=}}
 '''mTOR ihibitors'''
@@ Zeile 212: / Zeile 220: @@
 {{ttp|p=32337769|t=2020. (tt bradykinin) Noscapine, a possible drug candidate for attenuation of cytokine release associated with SARS-CoV-2 |pdf=|usr=}}
 {{tp|p=32359101|t=2020. A hypothesized role for dysregulated bradykinin signaling in COVID-19 respiratory complications |pdf=|usr=}}
+'''Erythropoietin'''
+{{tp|p=32270515|t=2020. Does recombinant human Erythropoietin administration in critically ill COVID-19 patients have miraculous therapeutic effects?|pdf=|usr=}}
+'''Celastrol'''
+{{tp|p=32347602|t=2020. Should we try the antiinflammatory natural product, celastrol, for COVID-19?|pdf=|usr=}}
+'''1'''
+{{tp|p=32352871|t=2020. A Radiation Mitigator as a Potential Treatment for COVID-19 |pdf=|usr=}}
+'''Ozone'''
+{{tp|p=C7203037|t=ä. (Vitamin-C; Ozone)Two known therapies could be useful as adjuvant therapy in critical patients infected by COVID-19? |pdf=|usr=}}
+'''Thalidomide'''
+{{tp|p=C7186126|t=ä. Proposed use of thalidomide for the cytokine storm of COVID-19 |pdf=|usr=}}
+'''stimulating the Platelets'''
+{{ttp|p=32315397|t=2020. Promoting platelets is a therapeutic option to combat severe viral infection of the lung |pdf=|usr=}}
+'''Thrombomodulin'''
+{{tp|p=23607598|t=2013. (x)Involvement of high mobility group box 1 and the therapeutic effect of recombinant thrombomodulin in a mouse model of severe acute respiratory distress  syndrome |pdf=|usr=}}
+'''Chlorpromazine'''
+{{tp|p=32387014|t=ä. Repositionnement de la chlorpromazine ... |pdf=|usr=}}''psychiatric patients could be protected from severe forms of COVID-19 by their psychotropic treatments''
+*[https://www.biorxiv.org/content/10.1101/2020.05.05.079608v1 paper]
+'''nAChR as target'''
+{{tp|p=32387130|t=ä. GTS-21, an alpha7nAChR agonist, suppressed the production of key inflammatory mediators by PBMCs that are elevated in COPD patients and associated with impaired lung function |pdf=|usr=}}
+'''Lithium'''
+{{tp|p=32408073|t=2020. Lithium for the 2019 novel coronavirus |pdf=|usr=}}
+'''Resolvins'''
+{{tp|p=32416413|t=2020. Covid-19 management with inflammation resolving mediators? Perspectives and potential |pdf=|usr=}}
+'''beta adrenergic antagonists'''
+{{tp|p=32388480|t=2020. Can beta-adrenergic blockers be used in the treatment of COVID-19?|pdf=|usr=}}
+'''Copper'''
+{{tp|p=32388476|t=2020. Is copper beneficial for COVID-19 patients?|pdf=|usr=}}
+'''5-Fluorouracil 5-FU'''
+{{tp|p=32438240|t=2020. 5-Fluorouracil in combination with deoxyribonucleosides and deoxyribose as possible therapeutic options for the Coronavirus, COVID-19 infection |pdf=|usr=}}
+'''Nitric oxide'''
+{{tp|p=32387333|t=ä. Could nasal nitric oxide help to mitigate the severity of COVID-19?|pdf=|usr=}}

Other single compounds

Version vom 18. Juni 2020, 13:56 Uhr

Meine Werkzeuge

Namensräume

Varianten

Ansichten

Aktionen

Suche

Navigation

Werkzeuge